



TSX-V: VRS
OTCQX: VRSEF

TRANSFER AGENT

Olympia Transfer Services, Inc.
920-120 Adelaide Street W
Toronto, ON M5H 1T1

**3-MO AVG. DAILY
TRADING VOLUME**
281,731

Share Capital

As of January 7, 2014
Total issued and outstanding
shares
78,623,777

Total fully diluted shares
93,182,077

Trading at January 7, 2014
CDN \$0.27

52 week High
CDN \$0.64

52 Week Low
CDN \$0.17

Market Capitalization
\$20.8 Million

Contact

Verisante Technology, Inc.
306 - 2309 West 41st Ave.
Vancouver BC V6M 2A3
Tel 604 605 0507
Fax 604 605 0508

info@verisante.com

About Verisante Technology, Inc.

Verisante Technology, Inc. is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Company has licensed a revolutionary, patent-protected, platform technology from the British Columbia Cancer Agency. Using this technology, Verisante has developed Aura™, an award-winning device for the detection of skin cancer. Aura™ is already approved for sale in Canada, the EU, and Australia. Preliminary sales of Aura™ have commenced, with a full market release scheduled for 2014.

Verisante is also in the process of using this technology to develop Core™ for the detection of cancers within the body. The clinical study using Core™ to detect lung cancer has already been completed, with results to be published in the near term. Studies for colon cancer, nasopharyngeal cancer, and brain cancer are also underway.

Other products in the pipeline include a Multispectral Imaging Camera (for skin and oral cancer), and the ClearVu Elite™ for internal cancers.

Investment Highlights

- Award-winning, patent-protected, platform technology applicable to many forms of cancer
- Near-term revenue opportunity:
 - + Aura™: preliminary sales have begun, full market launch 2014
 - + VRS Research Unit to be launched 2014
 - Global spectrometry market worth USD 10.2 billion in 2011
- Transparency Market Research
- Upcoming milestones:
 - + Aura™: Application for FDA approval in the US
 - + Core™: Clinical study for lung cancer detection completed, full results to be released
 - Clear regulatory pathway for Health Canada approval
 - Studies underway for colon, nasopharyngeal, and oral cancer
- MSI phase two prototype complete
- Project management led by experienced, award-winning pioneers
- Medical and technical team led by renowned experts
- Highly qualified management
- Strong, independent board

Product Pipeline



Aura™ for skin cancer detection

- World's first
- Uses same platform technology as Core™ and VRS Research unit
 - + Unique operating software and fiber optic skin probe
- Real-time, objective, non-invasive diagnosis of all major skin cancers
- Clinical study results published in the peer-reviewed journal *Cancer Research*
- Award-winning technology; recognized by Popular Science, SPIE, and the Edison Awards
- Preliminary sales in 2013; full market launch 2014
- 1 in 5 Americans and 1 in 7 Canadians will be diagnosed with skin cancer in their lifetime

MSI for oral and skin cancer detection

- Captures images of 18 different wavelengths of light in 1/3 of a second
- HD multispectral images provide useful information to assist in cancer detection
- CDT code ("D0431") for oral cancer reimbursement already available in the United States
- May be used in conjunction with Aura™ or as a standalone device
- Current stage: Phase 2 prototype complete (imaging camera for skin cancer)



Core™ for cancers within the body

- Uses same platform technology as Aura™ and VRS Research Unit
 - + Unique operating software and endoscopic probe
- Provides instant feedback for Raman measurements and aids in real-time clinical diagnosis
- Studies underway for colon, nasopharyngeal, oral, esophageal and stomach cancers
- Clinical Study for lung cancer detection complete; full results from to be released soon
- Named by the Canadian Cancer Society as one of the "Top 10 breakthroughs of 2011"

VRS Research unit

- Jointly developed by the BC Cancer Agency, University of British Columbia and Verisante
- Exclusively licensed, patent-protected technology
- Uses same platform technology as Aura™ and Core™
 - + Custom probe design capabilities
- Fastest fiber optic Raman spectrometer in the world
- Signal acquisition time of under one second



This fact sheet contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.